VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
How did VNRX's recent EPS compare to expectations?
The most recent EPS for VolitionRX Ltd is $-0.05, beating expectations of $-0.04.
How did VolitionRX Ltd VNRX's revenue perform in the last quarter?
VolitionRX Ltd revenue for the last quarter is $-0.05
What is the revenue estimate for VolitionRX Ltd?
According to 6 of Wall street analyst, the revenue estimate of VolitionRX Ltd range from $630.0K to $490.0K
What's the earning quality score for VolitionRX Ltd?
VolitionRX Ltd has a earning quality score of B+/47.830894. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does VolitionRX Ltd report earnings?
VolitionRX Ltd next earnings report is expected in 2026-06-29
What are VolitionRX Ltd's expected earnings?
VolitionRX Ltd expected earnings is $780.47K, according to wall-street analysts.
Did VolitionRX Ltd beat earnings expectations?
VolitionRX Ltd recent earnings of $447.03K does not beat expectations.